Last updated: May 30, 2026
Suppliers for MARLISSA (extended-cycle levonorgestrel and ethinyl estradiol): who manufactures active ingredients, tablets, and packaging?
No complete, accurate supplier map can be produced from the information provided.
What company supplies MARLISSA for patients in the US (active ingredient and finished-dose manufacturing)?
A supplier profile for MARLISSA requires verified, drug-specific sourcing data across:
- finished-dose manufacturer(s) listed on the FDA label (or SPL submissions),
- active pharmaceutical ingredient (API) manufacturers (often not disclosed publicly),
- packaging/labeling contractors (also typically not disclosed on the label).
With only the product name “MARLISSA” and no label or FDA record details, a precise supplier list cannot be constructed.
What is the FDA label manufacturer for MARLISSA tablets and who is the applicant/distributor?
FDA label “Manufactured for” and “Distributed by” lines identify the applicant and finished-dose manufacturer. Supplier mapping depends on extracting those lines from the current US prescribing information, which is not included in the input.
Which API suppliers make levonorgestrel and ethinyl estradiol used in MARLISSA?
API suppliers are typically not listed directly for oral contraceptives in public label text. A complete supplier list requires:
- inspection-level supply chain data, or
- a specific database extract tied to MARLISSA (DMF cross-references and manufacturing sites), or
- a confirmed ANDA/505(b)(2) reference listing that discloses the reference listed drug’s manufacturing information.
No such MARLISSA-specific records are provided.
What packaging and labeling contractors supply MARLISSA (blistering, bottling, imprinting)?
Oral contraceptives commonly use third-party packaging (bottling/blister) under contract. Public disclosures are inconsistent and product-specific. A correct answer requires confirmed packaging site data for MARLISSA.
How does MARLISSA’s supplier chain compare with other levonorgestrel/ethinyl estradiol brands?
Comparable-brand analysis requires knowing the exact active and dosage form (and whether MARLISSA is a specific extended-cycle regimen). With only the brand name, a direct comparison of supplier estates across peers cannot be validated.
What is the Orange Book status of MARLISSA, and does that identify supplier sites?
The Orange Book can indicate listed drug, applicant, and some patent/exclusivity ties, but it does not generally provide a full supplier chain. A verified Orange Book record for MARLISSA is required to answer this precisely.
What generic or 505(b)(2) challengers for MARLISSA exist and do they disclose reference-label suppliers?
Paragraph IV and 505(b)(2) filings may disclose reference product manufacturing details in certain documents, but the filings are not provided. Without MARLISSA-specific litigation and submission data, supplier identification risks inaccuracy.
Key Takeaways
- A supplier list for MARLISSA cannot be produced without MARLISSA-specific FDA label and/or SPL record details that identify the finished-dose manufacturer, applicant, and any disclosed manufacturing sites.
- API and packaging supplier disclosure is not reliably inferable from the product name alone.
FAQs
- Where on the MARLISSA label do finished-dose manufacturer and distributor appear?
- Does the Orange Book list MARLISSA manufacturing sites or only legal applicant/patent information?
- Are levonorgestrel and ethinyl estradiol API suppliers disclosed for oral contraceptives?
- Do generic challenges (ANDA/505(b)(2)) reveal reference product manufacturing contractors?
- How can MARLISSA’s manufacturing sites be verified from FDA records?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database; MARLISSA record not provided in input).
